Keywords: Bayer, Onyx, Regorafenib, US priority review, Anthera Pharma, Blisibimod

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

Article | 29 June 2012

Print This

Bayer HealthCare, a US unit of Germany’s Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in